Metabolic Peptides

Peptides studied for metabolic function, weight management, and energy regulation. Includes research on compounds affecting metabolism and body composition.

17 articles

BRP: Stanford's 12-Amino-Acid 'Natural Ozempic' That Skips the Nausea

A Stanford team used a computational pipeline called Peptide Predictor to comb through 2,683 hypothetical human peptide fragments and pull out a 12-mer they named BRP. In mice and minipigs it cut food intake by up to 50% in an hour and stripped fat without touching lean mass — and it didn't go anywhere near the GLP-1 receptor. Here's what the Nature paper actually shows, what it doesn't, and why it might matter even more than another incretin.

Metabolic Peptides

Pemvidutide: The GLP-1/Glucagon Peptide That Just Got FDA Breakthrough Status for MASH

In January 2026, the FDA granted Altimmune's pemvidutide Breakthrough Therapy Designation for MASH after Phase 2b data showed 54.7% liver fat reduction, meaningful fibrosis improvement, and a lipid profile unlike anything else in the GLP-1 class. Here's what the data actually shows—and why Phase 3 could reshape fatty liver treatment.

Metabolic Peptides

MariTide: The Once-a-Month Shot That Flips the GIP Script on Obesity

Amgen's MariTide is an antibody-peptide conjugate that activates GLP-1 while blocking GIP — the exact opposite of tirzepatide — and only needs to be injected once a month. Phase 2 data showed up to 20% weight loss, and Phase 3 MARITIME trials are now enrolling thousands. Here's why this drug could reshape the obesity treatment calendar.

Metabolic Peptides

Amycretin: The Single-Molecule Dual Agonist That Could Make Ozempic Look Like a First Draft

Novo Nordisk's amycretin crams GLP-1 and amylin activity into one molecule — delivering up to 22% weight loss in early trials, available as both a shot and a pill, and heading into Phase 3 in 2026. Here's the science, the data, and what it means for the future of obesity treatment.

Metabolic Peptides

Orforglipron: The GLP-1 Pill That Isn't a Peptide — And Why That Changes Everything

Eli Lilly's orforglipron could become the first non-peptide oral GLP-1 drug approved by the FDA. With a PDUFA date of April 2026, NEJM-published Phase 3 data showing 11.2% weight loss, and head-to-head superiority over oral semaglutide, here's what the clinical evidence actually says — and why a small molecule beating peptides at their own game matters more than you think.

Metabolic Peptides

CagriSema: The Amylin-GLP-1 Combo That Could Change the Weight Loss War

Novo Nordisk's CagriSema pairs an amylin analog with semaglutide to attack appetite from two directions at once. With 22.7% weight loss in Phase 3, an FDA filing already submitted, and a dramatic head-to-head showdown against tirzepatide, here's what the clinical data actually shows.

Metabolic Peptides

Survodutide and MASH: The Dual Agonist Taking Aim at the Liver Disease Epidemic

With up to 62% of patients achieving MASH resolution in Phase 2 trials—roughly double the only approved drug—Boehringer Ingelheim's GLP-1/glucagon dual agonist could reshape how we treat the world's most common liver disease. Here's what the data shows.

Metabolic Peptides

Retatrutide: The Triple Agonist That's Rewriting the Weight Loss Playbook

With nearly 29% average weight loss in trials—double what Ozempic delivers—Eli Lilly's triple hormone agonist is generating massive buzz. Here's what the science actually shows, when it might be available, and what those online discussions aren't telling you.

Metabolic Peptides

GLP-1 and Addiction: Can Ozempic Really Cure Your Cravings?

Thousands of patients report losing interest in alcohol, gambling, and even shopping after starting GLP-1 drugs. The science behind these claims is both promising and complicated—and it's reshaping how we think about addiction.

Metabolic Peptides

GLP-1 and Brain Health: What the EVOKE Trial Failure Actually Tells Us

The EVOKE trials failed to show semaglutide slows Alzheimer's progression. Headlines called it a setback. But the full story is more nuanced—and more interesting. Real-world data still shows 40-70% reduced dementia risk in GLP-1 users. The lesson isn't that GLP-1s don't help the brain. It's that timing might be everything.

Metabolic Peptides

MOTS-c: The Exercise Mimetic Peptide Reshaping Metabolic Research

MOTS-c is a mitochondrial-derived peptide that mimics the metabolic benefits of exercise by activating AMPK and improving insulin sensitivity. Recent 2025 research breakthroughs in diabetic heart disease and pancreatic aging have accelerated interest in this unique peptide.

Metabolic Peptides

Oral Wegovy Launches in the US: A New Era for GLP-1 Peptide Therapy

The FDA has approved the first oral GLP-1 medication for weight loss, and Novo Nordisk's Wegovy pill is now available at US pharmacies. This breakthrough in peptide delivery technology could fundamentally change how millions access obesity treatment.

Metabolic Peptides

Weight Loss Peptides: A Comprehensive Research Overview

An evidence-based overview of peptides researched for weight management, including GLP-1 agonists, growth hormone peptides, and metabolic regulators, with clinical trial data and comparisons.

Metabolic Peptides

Semaglutide FAQ: 20 Common Questions Answered

Answers to the 20 most frequently asked questions about semaglutide, covering mechanism, efficacy, side effects, comparisons with other GLP-1 agonists, and what research shows.

Metabolic Peptides

Comparison18 min

Semaglutide vs Tirzepatide: A Comprehensive Comparison of GLP-1 Peptides

An evidence-based comparison of semaglutide and tirzepatide, examining their mechanisms, clinical trial results, efficacy for weight management, and key differences in research outcomes.

Metabolic Peptides

The GLP-1 Backlash Is Coming — And Most of the Criticism Misses the Point

As GLP-1 agonists go mainstream, the inevitable backlash has begun. Critics warn of muscle loss, dependency, and 'taking the easy way out.' Some concerns are valid. Most miss the point entirely. Here's my take on what the skeptics get right—and where they go wrong.

Metabolic Peptides

Retatrutide: The Triple Agonist That Could Redefine Obesity Treatment

Retatrutide is Eli Lilly's experimental triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show unprecedented weight loss of up to 24%. Here's what the research reveals.

Metabolic Peptides

Showing 17 articles in Metabolic Peptides

Explore more categories

Browse all research categories or explore our peptide database.

All Categories Peptide Database